Esperion Theraptc Cm (ESPR) 11.14 $ESPR Esperion (ESPR)

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 12:08 PM

Esperion Theraptc Cm (ESPR) 11.14 $ESPR

Esperion (ESPR) Offers Updates on LDL-Lowering Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 10:09AM CDT
Esperion (ESPR) announced updates on a clinical development program as well as its regulatory plans for lead candidate, bempedoic acid (ETC-1002).
ESPR: 11.14 (-0.05), ANIP: 56.14 (-0.37), PFE: 36.24 (+0.12), BMY: 75.48 (+0.20)

Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid
GlobeNewswire - Tue Jun 28, 3:05PM CDT
On track to initiate global pivotal Phase 3 studies and CVOT in the fourth quarter
ESPR: 11.14 (-0.05)

Looking Into Biotech's Crystal Ball
ACCESSWIRE - Thu May 19, 3:35PM CDT
LAS VEGAS, NV / ACCESSWIRE / May 19, 2016 / While biotech investing is riddled with risk it is also ripe with reward. One way we can mitigate risk in this rough and tumble sector that has made millionaires of many and bankrupted some is to pay attention to subtext and follow the company's true progress. Especially when dealing with development stage biotechs.
ESPR: 11.14 (-0.05)

Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 7:05AM CDT
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today provided bempedoic acid (ETC-1002) development program updates and financial results for the first quarter ended March 31, 2016.
ESPR: 11.14 (-0.05)

Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 11.14 (-0.05), CMRX: 3.94 (-0.05), GERN: 2.76 (+0.04), CYTX: 2.02 (+0.01), CLDX: 4.70 (+0.06), SGMO: 6.09 (-0.09), PTCT: 7.59 (+0.06), ATHX: 2.29 (unch), MNKD: 1.16 (-0.01)

IRRAS AB Appoints Anders P. Wiklund to its Board of Directors
PR Newswire Europe - Wed Mar 23, 7:01AM CDT
- Mr. Wiklund is a well recognized and seasoned healthcare executive
ESPR: 11.14 (-0.05)

Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 11.14 (-0.05), VCEL: 2.29 (+0.07), SGMO: 6.09 (-0.09), ZYNE: 7.28 (-0.08)

INVESTOR DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Esperion Therapeutics, Inc.
BusinessWire - Fri Mar 11, 8:35PM CST
Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(Nasdaq: ESPR) for potential violations of federal securities laws and breaches of the Esperion Board's fiduciary duties.
ESPR: 11.14 (-0.05)

March 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Esperion Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline
BusinessWire - Fri Mar 11, 8:30AM CST
Law Offices of Howard G. Smith reminds investors of the upcoming March 14, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(NASDAQ: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the "Class Period"

. Investors who suffered losses on their investment in Esperion securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights.
ESPR: 11.14 (-0.05)

Scott + Scott, LLP Notifies Investors That Monday, March 14, 2016 is Last Day to File Lead Plaintiff Papers in Esperion Therapeutics (ESPR) Securities Case
GlobeNewswire - Wed Mar 09, 7:45PM CST
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
ESPR: 11.14 (-0.05)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016
ACCESSWIRE - Wed Mar 09, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / March 11, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors of class action against Esperion Therapeutics, Inc. (Esperion or "the Company"

(Nasdaq: ESPR) and certain of its officers. The class action was filed in the United States District Court for the Eastern District of Michigan on behalf of a class consisting of all persons or entities who purchased shares from August 18, 2015 through September 28, 2015, all dates inclusive (the "Class Period"

. Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ESPR: 11.14 (-0.05)

Esperion Therapeutics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Tue Mar 08, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today announced Tim M. Mayleben, president and chief executive officer, will present at the Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 15, 2016 at 8:30 A.M. Eastern Time.
ESPR: 11.14 (-0.05)

Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit against Esperion Therapeutics, Inc.
BusinessWire - Tue Mar 08, 9:30AM CST
Glancy Prongay & Murray LLP ("GPM"

reminds investors that a class action complaint has been filed on behalf of a class of investors who purchased Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(Nasdaq: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the "Class Period"

. Esperion investors have until March 14, 2016 to file a lead plaintiff motion. Investors are encouraged to contact GPM to discuss their legal rights.
ESPR: 11.14 (-0.05)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 14, 2016 - ESPR
PR Newswire - Tue Mar 08, 8:52AM CST
The following statement is being issued by Levi & Korsinsky, LLP:
ESPR: 11.14 (-0.05)

Scott + Scott, LLP Notifies Investors of Monday, March 14, 2016 Deadline in Esperion Therapeutics (ESPR) Securities Case
BusinessWire - Mon Mar 07, 10:39AM CST
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
ESPR: 11.14 (-0.05)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016
ACCESSWIRE - Mon Mar 07, 9:01AM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors of class action against Esperion Therapeutics, Inc. (Esperion or "the Company"

(NASDAQ: ESPR) and certain of its officers. The class action was filed in the United States District Court for the Eastern District of Michigan on behalf of a class consisting of all persons or entities who purchased shares from August 18, 2015 through September 28, 2015, all dates inclusive (the "Class Period"

. Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ESPR: 11.14 (-0.05)

Hagens Berman Reminds Esperion Therapeutics, Inc. (NASDAQGM: ESPR) Investors of March 14, 2016 Lead Plaintiff Deadline
GlobeNewswire - Mon Mar 07, 7:30AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors there is a March 14, 2016 lead plaintiff deadline in the securities fraud class action lawsuit filed against the Company related to the delayed approval of Esperion's leading cholesterol drug.
ESPR: 11.14 (-0.05)

SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Esperion Therapeutics, Inc.
BusinessWire - Fri Mar 04, 8:15PM CST
Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(Nasdaq: ESPR) for potential violations of federal securities laws and breaches of the Esperion Board's fiduciary duties.
ESPR: 11.14 (-0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hiromi Asai's Akatsuki Shines at Paris Fashion Week

An Ode to Tradition Amid Modern Menswear From the bustling avenues of New York to the storied streets of Paris, Hiromi Asai is showcasing something that strikes a chord deep in the fashion industry's soul. Her Spring/Summer 2027 collection, "Akatsuki — Before the Dawn," takes its rare blend of age-old Japanese textile craftsmanship across the pond to the City of Light....

Travelers Turn to Direct Booking Amid Cost Surge

Getting Ahead of the Travel Expense Game Rising fees and tighter budgets haven't persuaded holiday travelers to abandon their plans. Instead, they’re sharpening their axes, looking for clearer paths to their vacation goals without slicing off an arm and a leg. With the cost of travel climbing faster than a runaway elevator, folks are getting smart about where their...

Hot Property Alert: Prime Storage Facility Sale in Texas

Investment Gold in Abilene's Storage Sector Diving headfirst into the world of bricks and mortar, the opportunity brewing over in Abilene, Texas, packs a potent punch for anyone keen on beefing up their real estate portfolio with a top-notch asset. We're talking about Spare Feet Self Storage, a slick, Class A self-storage facility, serving the cream of the crop in a...

Dan Brown Joins Guidewire: Big Moves in P&C Software

Turning the Insurance World on Its Head Just when you think the enterprise software scene is getting predictable, along comes a bit of news to shake things up. Guidewire, a name known in the P&C insurance software world, has roped in a veteran—Dan Brown—who's got more than a quarter-century under his belt shaping product strategies. It’s not just another suit...

ProClad Unveils Innovative Hybrid 2.0 Cookware

Revolutionizing Cookware: The Launch of Hybrid 2.0 Today, everyone's buzzing about ProClad's big reveal—the Hybrid 2.0 Pan. Now, before you roll those skeptical eyes, hear me out. This isn’t your average bit of kitchen fluff; it’s a heavyweight contender stepping into the everyday cooking ring. What they've done here is combine the muscle of stainless steel searing...

Metropolitan Dermatology's Strategic Expansion into Barnegat

Diving into Barnegat's Dermatology Landscape Metropolitan Dermatology has taken a strategic step by opening a new location right in the heart of Barnegat, New Jersey. Talk about a win-win for the folks in Ocean County. This isn't just another clinic opening up shop; it's about bringing comprehensive medical and surgical dermatologic care straight to the people who need...

Event Industry Power 50 Voting Surge Ahead of Close

An Unexpected Wave of Enthusiasm in Event Industry The Event Industry Power 50 is getting some serious action this year. Over 3,500 votes have already rolled in, smashing last year's numbers with days still left on the clock. It seems like folks can't wait to see their favorite event powerhouses crowned at this year's gala, which kicks off October 27 in New York City....

Palm Beach Royals Boost Pickleball's Popularity Surge

A New Era for Pickleball in Palm Beach It might be time to re-evaluate pickleball if you weren't paying attention before. The Palm Beach Royals have wrapped up their first Major League Pickleball season with a bang, marking a pivotal year for the sport. This underdog tale of graft and grit is carving out a new chapter in the world of sport. Record-Breaking Season for MLP...

Aging at Home: The Real Costs and Obstacles Ahead

Facing the Realities of Aging In Place Alright, let's talk straight. Everyone dreams of staying home in their twilight years, kicking back in their favorite chair with family nearby. But the harsh truth? That comfort comes with a price tag. According to Northwestern Mutual's 2026 Planning & Progress Study, up to 83% of Boomers+ and most other generations fancy the idea of...

China Automotive Systems Hits Milestone with ASPICE 4.0 CL2

An Automotive Feat in R&D Now here's a story that should make waves across the automotive sector. China Automotive Systems, Inc. (NASDAQ: CAAS), a titan of power steering development in China, has nailed it by meeting the ASPICE 4.0 Capability Level 2. That's a big one, folks. Verified by a partnership between a European automaker and UL, this achievement is no fluke....